Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.

Multiple, dissimilar genetic defects in cancers of the same origin contribute to heterogeneity in tumor phenotypes and therapeutic responses of patients, yet the associated molecular mechanisms remain elusive. Here, we show at the systems level that serous ovarian carcinoma is marked by the activation of interconnected modules associated with a specific gene set that was derived from three independent tumor-specific gene expression data sets. Network prediction algorithms combined with preestablished protein interaction networks and known functionalities affirmed the importance of genes associated with ovarian cancer as predictive biomarkers, besides "discovering" novel ones purely on the basis of interconnectivity, whose precise involvement remains to be investigated. Copy number alterations and aberrant epigenetic regulation were identified and validated as significant influences on gene expression. More importantly, three functional modules centering on c-Myc activation, altered retinoblastoma signaling, and p53/cell cycle/DNA damage repair pathways have been identified for their involvement in transformation-associated events. Further studies will assign significance to and aid the design of a panel of specific markers predictive of individual- and tumor-specific pathways. In the parlance of this emerging field, such networks of gene-hub interactions may define personalized therapeutic decisions.

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  A. Berchuck,et al.  Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer , 2010, International journal of cancer.

[3]  S. Bapat,et al.  Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. , 2009, Cancer research.

[4]  A. Ghanate,et al.  Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53‐Mediated Apoptosis and Acquiring a Stem‐Like Phenotype in Ovarian Cancer Cells , 2009, Stem cells.

[5]  C. Plass,et al.  Copy number gain and oncogenic activity of YWHAZ/14‐3‐3ζ in head and neck squamous cell carcinoma , 2009, International journal of cancer.

[6]  C Caldas,et al.  Molecular classification of solid tumours: towards pathway-driven therapeutics , 2009, British Journal of Cancer.

[7]  Kai Stoeber,et al.  Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma , 2009, Clinical Cancer Research.

[8]  Jingqin Luo,et al.  Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome , 2009, Clinical Cancer Research.

[9]  Takako Sasaki,et al.  Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker , 2009, International journal of cancer.

[10]  S. Bapat,et al.  CD133‐Expressing Stem Cells Associated with Ovarian Metastases Establish an Endothelial Hierarchy and Contribute to Tumor Vasculature , 2009, Stem cells.

[11]  S. Gayther,et al.  Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers , 2009, PLoS medicine.

[12]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[13]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[14]  B. Karlan,et al.  Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target , 2008, Genes, chromosomes & cancer.

[15]  J. Astola,et al.  Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues , 2008, Genome Biology.

[16]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[17]  M. Mansukhani,et al.  Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression , 2008, Genes, chromosomes & cancer.

[18]  John L Hopper,et al.  Multiple loci with different cancer specificities within the 8q24 gene desert. , 2008, Journal of the National Cancer Institute.

[19]  Gang Meng,et al.  Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. , 2008, Experimental and molecular pathology.

[20]  Leslie Cope,et al.  Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis , 2008, PLoS medicine.

[21]  L. Myeroff,et al.  Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells , 2008, Genes, chromosomes & cancer.

[22]  Carolyn J. Brown,et al.  Epigenetics of cancer progression. , 2008, Pharmacogenomics.

[23]  Y. Miyagi,et al.  Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. , 2007, Cancer research.

[24]  M. Bieda,et al.  Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes , 2007, Proceedings of the National Academy of Sciences.

[25]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[26]  S. Bapat,et al.  Nuclear–mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells , 2006, Oncogene.

[27]  I. Shih,et al.  Chromosomal losses of regions on 5q and lack of high‐level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma , 2006, Genes, chromosomes & cancer.

[28]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[29]  H. Sakurai,et al.  The DNA-binding domain of yeast Hsf1 regulates both DNA-binding and transcriptional activities. , 2006, Biochemical and biophysical research communications.

[30]  N. Kaminski,et al.  Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. , 2006, Cancer research.

[31]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[32]  V. Moreno,et al.  Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy , 2005, Oncogene.

[33]  M. McClelland,et al.  “Promoter Array” Studies Identify Cohorts of Genes Directly Regulated by Methylation, Copy Number Change, or Transcription Factor Binding in Human Cancer Cells , 2005, Annals of the New York Academy of Sciences.

[34]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[35]  Shingo Matsumoto,et al.  Loss of imprinting of PEG1/MEST in lung cancer cell lines. , 2004, Oncology reports.

[36]  Chris Wiggins,et al.  ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context , 2004, BMC Bioinformatics.

[37]  M. Campbell,et al.  PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.

[38]  U. Löhrs,et al.  CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. , 2002, American journal of clinical pathology.

[39]  T. Goto,et al.  Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. , 2001, Human cell.

[40]  M. Veigl,et al.  Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation. , 2001, Cancer research.

[41]  Jianmin Wu,et al.  Integrated network analysis platform for protein-protein interactions , 2009, Nature Methods.

[42]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.